ArticleCancer medicine2025
Exploring the Relationship Between Adipocytokines and Endometrial Cancer: Identifying Correlations With Clinico-Pathological Prognostic Factors.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Obesityand Gynaecological Cancers, with a Focus on Morbid Obesity: Risk Stratification, Early Diagnosis and Management.Diagnostics (Basel, Switzerland) · 2026Review
- Exploring the Relationship Between Adipocytokines and Endometrial Cancer: Identifying Correlations With Clinico-Pathological Prognostic Factors.Cancer medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundEndometrial cancer, a malignancy linked with obesity, may be influenced by adipocytokines signalling due to chronic inflammation. This study explores the molecular expression patterns of adiponectin, leptin, interleukin6 (IL6), tumor necrosis factor (TNF)α, and their receptors in endometrial cancer patients and associations with lymphovascular space invasion (LVSI) and other tumour characteristics.
methodsWe analysed mRNA expression levels of the above biomarkers in endometrial cancer tissue using quantitative reverse transcriptase polymerase chain reaction (qRT-PCR), comparing them to benign endometrial tissue controls. Additionally, expressions in adipose tissue and lymph nodes were assessed, with correlations drawn between biomarker expression, patient demographics, and tumor characteristics.
resultsUsing qRT-PCR analysis, endometrial cancer tissues (n = 39) exhibited higher expression levels of adiponectin, leptin, IL6, TNFα, and their receptors, IL6R and TNFRSF1A/B, compared to the calibrator sample, which consisted of five pooled benign endometrial control samples. Intriguingly, the adiponectin receptors, ADIPOR1 and ADIPOR2 demonstrated opposing correlations with cancer characteristics such as grade, histology, LVSI, and microcystic elongated and fragmented (MELF) pattern. LVSI was linked to increased levels of markers such as IL6R and ADIPOR2, along with decreased expressions of OBR (leptin receptor) and ADIPOR1, suggesting their potential as surrogate markers for diagnosing LVSI. Notably, higher adiponectin expression was observed in the cancerous lymph nodes of patients with LVSI, contrasting with those without LVSI.
conclusionThis study provides novel insight into differential role of adiponectin receptors in endometrial cancer and the associations of various markers with LVSI, emphasizing the need for tissue-specific biomarker assessments in determining treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.